Menu
Giotrif® (afatinib) approved in Europe as new oral treatment option for patients with ...
- Approval provides a new oral treatment option for patients with the second largest sub-type of non-small cell lung cancer (NSCLC), representing approximately 20-30% of NSCLC cases
- Approval of Giotrif® is based on results of the LUX-Lung 8 study, which showed significantly improved overall survival and progression-free survival compared to Tarceva® (erlotinib) in patients with squamous cell carcinoma of the lung
- Afatinib is already approved in more than 60 countries for the treatment of patients with EGFR mutation-positive NSCLC*
(BUSINESS WIRE)-- Boehringer Ingelheim today announced that the http://me-newswire.net//news/17544/en...
Dans la même rubrique :
Jeudi 24 Avril 2025 - 11:40 Agro Talents 2025 : Un tremplin pour les jeunes passionnés d'agriculture au Tchad |
Jeudi 24 Avril 2025 - 09:20 La Force multinationale Mixte (FMM) livre un forage alimentation solaire à la communauté de Monguno |
Mercredi 23 Avril 2025 - 17:00 Tchad : le Conseil Islamique met en garde contre les discours haineux après des violences à Mangalmé |
